PMID- 34257619
OWN - NLM
STAT- MEDLINE
DCOM- 20220103
LR  - 20220103
IS  - 1532-2807 (Electronic)
IS  - 1219-4956 (Print)
IS  - 1219-4956 (Linking)
VI  - 27
DP  - 2021
TI  - MYCL1 Amplification and Expression of L-Myc and c-Myc in Surgically Resected 
      Small-Cell Lung Carcinoma.
PG  - 1609775
LID - 10.3389/pore.2021.1609775 [doi]
LID - 1609775
AB  - Purpose: The Myc family, especially C-MYC and MYCL1, has been found involved in 
      small-cell lung carcinoma (SCLC). Identification of the frequency of C-MYC and 
      MYCL1 expression among SCLC patients may help to identify potential targets for 
      therapeutic intervention. Our aim was to detect MYCL1 amplification, L-Myc and 
      c-Myc expression, and investigate clinicopathological characteristics and 
      survival status in patients with surgically resected SCLC. Methods: MYCL1 
      amplification was detected using fluorescence in situ hybridization (FISH), while 
      L-Myc and c-Myc protein expressions were determined using immunohistochemistry 
      (IHC) in the primary tumors of 46 resected SCLC patients. Results: Among the 46 
      evaluated specimens, MYCL1 amplification was identified in 3/46 cases (6.5%). One 
      of the positive cases was MYCL1 gene amplification combined with fusion. 3/46 
      (6.5%) was positive for L-myc protein expression, and 4/46 (8.7%) was positive 
      for c-Myc protein expression. Conclusion: Our study firstly multidimensional 
      explored the expression of MYCL1 amplification, L-Myc and c-Myc protein and 
      investigated clinicopathological characteristics and survival status in patients 
      with surgically resected SCLC, which makes a contribution to subsequent research 
      and therapeutic strategies.
CI  - Copyright (c) 2021 Qin, Xie, Li, Han and Lu.
FAU - Qin, Jing
AU  - Qin J
AD  - Department of Thoracic Medical Oncology, Cancer Hospital of the University of 
      Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic 
      Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
AD  - Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic 
      Oncology (Lung and Esophagus), Zhejiang Cancer Hospital, Hangzhou, China.
FAU - Xie, Fajun
AU  - Xie F
AD  - Department of Thoracic Medical Oncology, Cancer Hospital of the University of 
      Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic 
      Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
AD  - Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic 
      Oncology (Lung and Esophagus), Zhejiang Cancer Hospital, Hangzhou, China.
FAU - Li, Chenghui
AU  - Li C
AD  - Department of Thoracic Medical Oncology, Cancer Hospital of the University of 
      Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic 
      Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
FAU - Han, Na
AU  - Han N
AD  - Department of Thoracic Medical Oncology, Cancer Hospital of the University of 
      Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic 
      Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
FAU - Lu, Hongyang
AU  - Lu H
AD  - Department of Thoracic Medical Oncology, Cancer Hospital of the University of 
      Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic 
      Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
AD  - Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic 
      Oncology (Lung and Esophagus), Zhejiang Cancer Hospital, Hangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20210618
PL  - Switzerland
TA  - Pathol Oncol Res
JT  - Pathology oncology research : POR
JID - 9706087
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MYC protein, human)
RN  - 0 (MYCL protein, human)
RN  - 0 (Proto-Oncogene Proteins c-myc)
SB  - IM
MH  - Biomarkers, Tumor/genetics/*metabolism
MH  - Female
MH  - Follow-Up Studies
MH  - *Gene Amplification
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lung Neoplasms/genetics/metabolism/*pathology/surgery
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-myc/*genetics/*metabolism
MH  - Retrospective Studies
MH  - Small Cell Lung Carcinoma/genetics/metabolism/*pathology/surgery
MH  - Survival Rate
PMC - PMC8262133
OTO - NOTNLM
OT  - C-MYC
OT  - L-myc
OT  - MYCL1 amplification
OT  - fluorescence in situ hybridization
OT  - immunohistochemistry
OT  - small-cell lung carcinoma
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/07/15 06:00
MHDA- 2022/01/04 06:00
PMCR- 2021/06/18
CRDT- 2021/07/14 07:02
PHST- 2021/02/10 00:00 [received]
PHST- 2021/06/04 00:00 [accepted]
PHST- 2021/07/14 07:02 [entrez]
PHST- 2021/07/15 06:00 [pubmed]
PHST- 2022/01/04 06:00 [medline]
PHST- 2021/06/18 00:00 [pmc-release]
AID - 1609775 [pii]
AID - 10.3389/pore.2021.1609775 [doi]
PST - epublish
SO  - Pathol Oncol Res. 2021 Jun 18;27:1609775. doi: 10.3389/pore.2021.1609775. 
      eCollection 2021.